» Articles » PMID: 36759279

Assays to Quantify Fibrinolysis: Strengths and Limitations. Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on Fibrinolysis

Overview
Publisher Elsevier
Specialty Hematology
Date 2023 Feb 9
PMID 36759279
Authors
Affiliations
Soon will be listed here.
Abstract

Fibrinolysis is a series of enzymatic reactions that degrade insoluble fibrin. Plasminogen activators convert the zymogen plasminogen to the active serine protease plasmin, which cleaves and solubilizes crosslinked fibrin clots into fibrin degradation products. The quantity and quality of fibrinolytic enzymes, their respective inhibitors, and clot structure determine overall fibrinolysis. The quantity of protein can be measured by antigen-based assays, and both quantity and quality can be assessed using functional assays. Furthermore, variations of commonly used assays have been reported, which are tailored to address the role(s) of specific fibrinolytic factors and cellular elements (eg, platelets, neutrophils, and red blood cells). Although the concentration and/or activity of a protein can be quantified, how these individual components contribute to the overall fibrinolysis outcome can be challenging to determine. This difficulty is due to temporal changes within and around the thrombi during the clot breakdown, particularly the fibrin matrix structure, and composition. Furthermore, terms such as "fibrinolytic activity/potential," "plasminogen activation," and "plasmin activity" are often used interchangeably despite having different definitions. The purpose of this review is to 1) summarize the assays measuring fibrinolysis activity and potential, 2) facilitate the interpretation of data generated by these assays, and 3) summarize the strengths and limitations of these assays.

Citing Articles

Exploiting the Molecular Properties of Fibrinogen to Control Bleeding Following Vascular Injury.

Singh T, Hasan M, Gaule T, Ajjan R Int J Mol Sci. 2025; 26(3).

PMID: 39941103 PMC: 11818741. DOI: 10.3390/ijms26031336.


Evaluation of thrombomodulin/thrombin activatable fibrinolysis inhibitor function in plasma using tissue-type plasminogen activator-induced plasma clot lysis time.

Urano T, Sano Y, Suzuki Y, Okada M, Sano H, Honkura N Res Pract Thromb Haemost. 2024; 8(4):102463.

PMID: 39026660 PMC: 11255936. DOI: 10.1016/j.rpth.2024.102463.


Concentration-effect relationship for tranexamic acid inhibition of tissue plasminogen activator-induced fibrinolysis in vitro using the viscoelastic ClotPro® TPA-test.

Dibiasi C, Ulbing S, Bancher-Todesca D, Ulm M, Gratz J, Quehenberger P Br J Anaesth. 2023; 132(2):343-351.

PMID: 37925268 PMC: 10808820. DOI: 10.1016/j.bja.2023.09.027.


Illustrated State-of-the-Art Capsules of the ISTH 2023 Congress.

Kahn S, Arnold D, Casari C, Desch K, Devreese K, Favaloro E Res Pract Thromb Haemost. 2023; 7(4):100193.

PMID: 37538494 PMC: 10394567. DOI: 10.1016/j.rpth.2023.100193.

References
1.
HARDAWAY R, Brune W, GEEVER E, Burns J, Mock H . Studies on the role of intravascular coagulation in irreversible hemorrhagic shock. Ann Surg. 1962; 155:241-50. PMC: 1466037. DOI: 10.1097/00000658-196200000-00014. View

2.
Miszta A, Kopec A, Pant A, Holle L, Byrnes J, Lawrence D . A high-fat diet delays plasmin generation in a thrombomodulin-dependent manner in mice. Blood. 2020; 135(19):1704-1717. PMC: 7205812. DOI: 10.1182/blood.2019004267. View

3.
Van Bennekum A, Emeis J, Kooistra T, Hendriks H . Modulation of tissue-type plasminogen activator by retinoids in rat plasma and tissues. Am J Physiol. 1993; 264(5 Pt 2):R931-7. DOI: 10.1152/ajpregu.1993.264.5.R931. View

4.
Wu C, Kim P, Swystun L, Liaw P, Weitz J . Activation of protein C and thrombin activable fibrinolysis inhibitor on cultured human endothelial cells. J Thromb Haemost. 2015; 14(2):366-74. DOI: 10.1111/jth.13222. View

5.
Ilich A, Kumar V, Ferrara M, Henderson M, Noubouossie D, Jenkins D . Euglobulin clot lysis time reveals a high frequency of fibrinolytic activation in trauma. Thromb Res. 2021; 204:22-28. PMC: 8277746. DOI: 10.1016/j.thromres.2021.05.017. View